These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36555568)

  • 41. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist.
    Natesan S; Reckless GE; Barlow KB; Odontiadis J; Nobrega JN; Baker GB; George SR; Mamo D; Kapur S
    Psychopharmacology (Berl); 2008 Aug; 199(2):275-89. PubMed ID: 18521575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
    López-Gil X; Artigas F; Adell A
    Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
    Brindisi M; Butini S; Franceschini S; Brogi S; Trotta F; Ros S; Cagnotto A; Salmona M; Casagni A; Andreassi M; Saponara S; Gorelli B; Weikop P; Mikkelsen JD; Scheel-Kruger J; Sandager-Nielsen K; Novellino E; Campiani G; Gemma S
    J Med Chem; 2014 Nov; 57(22):9578-97. PubMed ID: 25343529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat.
    Pietraszek M; Michaluk J; Romańska I; Wasik A; Gołembiowska K; Antkiewicz-Michaluk L
    Neurotox Res; 2009 Nov; 16(4):390-407. PubMed ID: 19649683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
    Jantschak F; Brosda J; Franke RT; Fink H; Möller D; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2013 Oct; 347(1):57-68. PubMed ID: 23863695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride.
    Martin P; Waters N; Waters S; Carlsson A; Carlsson ML
    Eur J Pharmacol; 1997 Sep; 335(2-3):107-16. PubMed ID: 9369362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
    Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
    Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atypical antipsychotic profile of flunarizine in animal models.
    Tort AB; Dall'Igna OP; de Oliveira RV; Mantese CE; Fett P; Gomes MW; Schuh J; Souza DO; Lara DR
    Psychopharmacology (Berl); 2005 Jan; 177(3):344-8. PubMed ID: 15290004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia.
    Feng Z; Hu Z; Li L; Yu M; Zhang Y; Jing P; Xu X; Wu J; Hu Y; Xu X
    Front Pharmacol; 2024; 15():1298061. PubMed ID: 38327987
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
    Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
    Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia.
    Cortez IL; Silva NR; Rodrigues NS; Pedrazzi JFC; Del Bel EA; Mechoulam R; Gomes FV; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jul; 117():110553. PubMed ID: 35341823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
    Gyertyán I; Sághy K; Laszy J; Elekes O; Kedves R; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Agai Csongor E; Domány G; Kiss B; Szombathelyi Z
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):529-39. PubMed ID: 18548231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HBK-7 - A new xanthone derivative and a 5-HT1A receptor antagonist with antidepressant-like properties.
    Pytka K; Kazek G; Siwek A; Mordyl B; Głuch-Lutwin M; Rapacz A; Olczyk A; Gałuszka A; Waszkielewicz A; Marona H; Sapa J; Filipek B; Zygmunt M
    Pharmacol Biochem Behav; 2016; 146-147():35-43. PubMed ID: 27132236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.
    Sonego AB; Gomes FV; Del Bel EA; Guimaraes FS
    Behav Brain Res; 2016 Aug; 309():22-8. PubMed ID: 27131780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MK-801 and amphetamine result in dissociable profiles of cognitive impairment in a rodent paired associates learning task with relevance for schizophrenia.
    Talpos J; Aerts N; Waddell J; Steckler T
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):3911-20. PubMed ID: 25902874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.